Viking Therapeutics Inc (VKTX) — Cash Flow-to-Debt Ratio
Viking Therapeutics Inc (VKTX) has a Cash Flow-to-Debt Ratio of -1.11x as of December 2025, meaning its operating cash flow of $-85.29 Million could theoretically repay -1% of its total liabilities ($76.67 Million) in one year. See Viking Therapeutics Inc (VKTX) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Viking Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Viking Therapeutics Inc across 14 annual periods. For the full cash flow conversion analysis, see Viking Therapeutics Inc (VKTX) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for Viking Therapeutics Inc (2012–2025)
Year-by-year debt coverage analysis for Viking Therapeutics Inc. Check VKTX cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.15x | $-87.79 Million | $76.67 Million | ▲ +63.4% |
| 2024 | -3.13x | $-87.79 Million | $28.04 Million | ▲ +14.4% |
| 2023 | -3.66x | $-73.38 Million | $20.07 Million | ▼ -75.3% |
| 2022 | -2.09x | $-48.40 Million | $23.21 Million | ▲ +61.5% |
| 2021 | -5.42x | $-47.59 Million | $8.78 Million | ▼ -202.7% |
| 2020 | -1.79x | $-21.78 Million | $12.16 Million | ▲ +48.4% |
| 2019 | -3.47x | $-24.75 Million | $7.14 Million | ▲ +15.6% |
| 2018 | -4.11x | $-18.75 Million | $4.56 Million | ▼ -141.1% |
| 2017 | -1.70x | $-14.76 Million | $8.66 Million | ▲ +0.0% |
| 2016 | -1.71x | $-11.07 Million | $6.49 Million | ▼ -31.1% |
| 2015 | -1.30x | $-8.73 Million | $6.71 Million | ▼ -1957.0% |
| 2014 | -0.06x | $-1.59 Million | $25.17 Million | ▲ +65.2% |
| 2013 | -0.18x | $-78.23K | $431.00K | ▼ -9467.5% |
| 2012 | 0.00x | $-200.00 | $105.42K | — |